Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Blue Trust Inc.

Blue Trust Inc. raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 17.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,675 shares of the biopharmaceutical company’s stock after acquiring an additional 1,155 shares during the quarter. Blue Trust Inc.’s holdings in Gilead Sciences were worth $709,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in GILD. nVerses Capital LLC purchased a new position in Gilead Sciences in the 3rd quarter valued at about $25,000. Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $29,000. Valued Wealth Advisors LLC lifted its stake in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares during the period. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences during the second quarter worth approximately $33,000. Finally, Friedenthal Financial purchased a new stake in Gilead Sciences in the 3rd quarter worth approximately $50,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on GILD shares. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday. Barclays lifted their price target on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a report on Thursday, November 7th. Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Finally, UBS Group lifted their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $95.59 on Thursday. The company has a market cap of $119.13 billion, a PE ratio of 1,062.11, a P/E/G ratio of 1.31 and a beta of 0.18. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a fifty day moving average price of $92.00 and a two-hundred day moving average price of $85.44. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the prior year, the firm earned $2.29 EPS. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. Research analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the transaction, the insider now owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 456,234 shares of company stock worth $42,130,461. 0.16% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.